Comparison of the Effects of MCI-154, a New Cardiotonic Agent, and Some Ca<SUP>2+</SUP>-Sensitizing Agents on the Response of the Contractile System to Ca<SUP>2+</SUP> in Skinned Cardiac Muscle
スポンサーリンク
概要
- 論文の詳細を見る
Several cardiotonic agents (MCI-154, sulmazole, pimobendan and adibendan) were examined for their ability to influence Ca<SUP>2+</SUP>-activated tension development and MgATP-activated tension development in the absence of free Ca<SUP>2+</SUP> (rigor tension), using the chemically skinned fiber from guinea pig papillary muscles. MCI-154, sulmazole, pimobendan and adibendan all increased the tension development induced by pCa (-log[Ca<SUP>2+</SUP>]M) 5.8 in a concentration-dependent manner (10<SUP>-6</SUP> to 10<SUP>-4</SUP> M). The order of the potency was as follows: MCI-154>pimobendan>adibendan>sulmazole. MCI-154 enhanced the maximum tension developed at pCa 4.4 but sulmazole, pimobendan and adibendan did not enhance it. MCI-154, but not sulmazole, pimobendan and adibendan, enhanced the tension development induced by pMgATP (-log[MgATP]M) 6.0 in the absence of free Ca<SUP>2+</SUP>. MCI-154, sulmazole, pimobendan and adibendan concentration-dependently (10<SUP>-7</SUP> to 10<SUP>-4</SUP> M) increased the force of contraction in isolated guinea pig papillary muscles. The order of the potency was as follows: MCI-154> adibendan>pimobendan>sulmazole. These results demonstrated that the Ca<SUP>2+</SUP>-sensitizing action on the contractile system may be involved in the positive inotropic action of MCI-154, sulmazole, pimobendan and adibendan, and that MCI-154 is the most potent among these drugs. Furthermore, sulmazole, pimobendan and adibendan did not enhance the interaction of actin and myosin, suggesting that the mechanism of actions of these drugs are qualitatively different from that of MCI-154.
著者
-
Kitada Yoshimi
Pharmaceutical Laboratory I Yokohama Research Center Mitsubishi Chemical Corporation
-
MORITA Miyuki
Pharmaceuticals Laboratory, Life Science Research Sector, Research Center, Mitsubishi Kasei Corporation
-
NARIMATSU Akihiro
Pharmaceuticals Laboratory, Life Science Research Sector, Research Center, Mitsubishi Kasei Corporation
関連論文
- Betaxolol, a β_1 -Adrenoceptor Antagonist, Inhibits Ca^-Induced Contraction in Skinned Renal Artery of the Dog
- Comparison of the Effects of MCI-154, a New Cardiotonic Agent, and Some Ca2+-Sensitizing Agents on the Response of the Contractile System to Ca2+ in Skinned Cardiac Muscle
- In vitro characterization of the effects of MCI-154, anovel cardiotonic agent, on cardiac tissues.
- Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: Comparison with atenolol and propranolol.
- Betaxolol, a cardioselective beta-adrenoceptor antagonist, attenuates ischemic myocardial acidosis in dogs.